Clinical Trials Browser

Phase 3 × Denosumab × 90 days × Clear all

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms